Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05852041 · ClinicalTrials.gov registry record · Early Phase 1
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
A Early Phase 1 study of Prostate Adenocarcinoma and Stage I Prostate Cancer AJCC v8, sponsored by Northwestern University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05852041: Recruiting Early Phase 1 study of Prostate Adenocarcinoma and Stage I Prostate Cancer AJCC v8, sponsored by Northwestern University.
NCT05852041 is a Early Phase 1 study of Prostate Adenocarcinoma and Stage I Prostate Cancer AJCC v8 that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 40 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05852041, a Early Phase 1 study of Prostate Adenocarcinoma and Stage I Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer who are candidates for active surveillance. A PET scan is a test that uses a radioactive drug and a computer to create images of how organs and tissues in the body are functioning. The radioactive drug used in this study, rhPSMA-7.3, attaches to the abnormal cells in the body at a different rate than normal cells which allows the scanner to create a detailed picture of how the body is working. An MRI scan uses strong magnets and computers to create detailed images of the soft tissue in your body. A multiparametric (mp)MRI is a type of MRI scan that creates a more detailed picture of the prostate gland. Using rhPSMA-73 with PET-MRI and mpMRI may be more effective in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate cancer.
Primary Outcome
Will report agreement between pathology and imaging and ability of radiohybrid prostate-specific membrane antigen-7-PET-MRI to identify higher grade and stage disease as a raw percentage.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Biopsy of Prostate
- GENETIC Decipher Prostate Cancer Test
- OTHER Flotufolastat F-18 Gallium
- PROCEDURE Multiparametric Magnetic Resonance Imaging
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2035-06-07 |
| Phase | Early Phase 1 |
What NCT05852041 shows while recruiting
NCT05852041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (82% lower).
The record links to 4 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT05852041 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05852041 about?
NCT05852041 is a clinical study titled "rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance". This clinical trial evaluates whether positron emission tomography-magnetic resonance imaging (PET-MRI) using the radioactive drug radiohybrid prostate-specific membrane antigen (rhPSMA)-7.3 may help in detecting higher grade or stage disease in men with low and favorable intermediate risk prostate ...
What is the current status of trial NCT05852041?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2023-06-07. Estimated completion is 2035-06-07.
What conditions does trial NCT05852041 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT05852041?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Biopsy of Prostate (PROCEDURE), Decipher Prostate Cancer Test (GENETIC), Flotufolastat F-18 Gallium (OTHER), Multiparametric Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT05852041?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05852041 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05852041's enrollment target sits among peer trials
40 71st of 99 higher than 28 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Intraoperative ICG on Functional Outc in RARP
RECRUITING · Early Phase 1
-
An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
RECRUITING · Early Phase 1
-
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
ACTIVE NOT RECRUITING · Early Phase 1
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
Customized TULSA-PRO Ablation Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI